Targeting Cancer Heterogeneity with Immune Responses Driven by Oncolytic Peptides.
Loading...
Embargo End Date
ICR Authors
Authors
Vitale, I
Yamazaki, T
Wennerberg, E
Sveinbjørnsson, B
Rekdal, Ø
Demaria, S
Galluzzi, L
Yamazaki, T
Wennerberg, E
Sveinbjørnsson, B
Rekdal, Ø
Demaria, S
Galluzzi, L
Document Type
Journal Article
Date
2021-01-11
Date Accepted
2020-12-15
Abstract
Accumulating preclinical and clinical evidence indicates that high degrees of heterogeneity among malignant cells constitute a considerable obstacle to the success of cancer therapy. This calls for the development of approaches that operate - or enable established treatments to operate - despite such intratumoral heterogeneity (ITH). In this context, oncolytic peptides stand out as promising therapeutic tools based on their ability to drive immunogenic cell death associated with robust anticancer immune responses independently of ITH. We review the main molecular and immunological pathways engaged by oncolytic peptides, and discuss potential approaches to combine these agents with modern immunotherapeutics in support of superior tumor-targeting immunity and efficacy in patients with cancer.
Citation
Trends in cancer, 2021
Source Title
Publisher
CELL PRESS
ISSN
2405-8033
eISSN
2405-8025
Collections
Research Team
Radiation-enhanced Immunotherapy
Radiation-enhanced Immunotherapy
Radiation-enhanced Immunotherapy